In 10–15% of GIST cases, PDGFRA substitutions can be found, mostly comprising an activating exon 18 D842V exchange, which encodes the activation domain that causes primary imatinib resistance [8]. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.